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A B S T R A C T
Background: Endothelial Progenitor Cells (EPCs) are a circulating stem cell population with in vivo capacity of
promoting angiogenesis after ischemic events. Despite the promising preclinical data, their potential integration
with reperfusion therapies and hemodynamic evolution of stroke patients is still unknown. Our aim was to
determine the association of EPCs with acute, subacute and chronic hemodynamic features.
Methods: In this prospective study, we included consecutive patients with ages between 18 and 80 years and
non-lacunar ischemic stroke within the territory of a middle cerebral artery. All patients were subject to he-
modynamic evaluation by ultrasound at baseline, seven days and three months. We quantified cerebral blood
flow (CBF) and assessed early recanalization and collateral flow. Hemorrhagic transformation was graded in
Magnetic Resonance imaging performed at seven days. EPCs were isolated from peripheral venous blood col-
lected in the first 24 h and seven days, counted and submitted to functional in vitro tests.
Results: We included 45 patients with a median age of 70 ± 10 years. The angiogenic and migratory capacities
of EPCs were associated with increased collateral flow in the acute stage and day seven CBF, without statistically
significant associations with recanalization nor haemorrhagic transformation. The number of EPCs was not
associated with any hemodynamic variable.
Conclusions: The functional properties of EPCs are associated with acute and subacute stroke hemodynamics,
with no effect on haemorrhagic transformation.
1. Introduction
The treatment algorithm for acute ischemic stroke has had sig-
nificant recent updates due to new effective strategies to promote re-
canalization. However, after the first few hours no therapy has de-
monstrated meaningful impact on clinical recovery. Endothelial
Progenitor Cells (EPCs) are circulating cells that have emerged as a
promising treatment strategy, with demonstrated in vivo capacity of
promoting neovascularization and neurological improvement after
stroke [1,2]. Nonetheless, their timing of action and integration within
stroke hemodynamics are still unknown, which can be critical for
optimization of their clinical effect.
Acute stroke hemodynamics have been recognized as one of the
main determinants of clinical evolution [3,4]. Several pathophysiolo-
gical mechanisms take place in the regulation of vascular responses
with distinct implications and at different timepoints. In the hyperacute
stage the main determinant of evolution is early recanalization, with a
marked clinical impact [5,6]. Collateral pial circulation and cerebral
blood flow (CBF) are also essential early hemodynamic mechanisms,
installed in the attempt to extend the preservation of cerebral tissue
after the vascular insult [7]. After the acute stage, and depending on
timing of recanalization and resistance to ischemia, a loss of
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autoregulation may precipitate hyperperfusion injury which may ulti-
mately lead to hemorrhagic transformation [8]. Altogether, these are
potentially modifiable hemodynamic responses, crucial to the clinical
evolution after stroke.
The potential integration of EPC transplantation within the treating
algorithm of stroke will have to take the hemodynamic response into
account. As such, in this study we used a multidimensional approach to
assess the interplay between EPCs and the several aspects of the pa-
tients' hemodynamic state.
2. Methods
2.1. Study population
We included consecutive acute ischemic stroke patients admitted in
our department during a period of 27 months (June/2012 to August/
2013 and June/2014 to July/2016) in a prospective observational co-
hort study. All patients with ages between 18 and 80 years and clini-
cally defined non-lacunar strokes within the territory supplied by the
Middle Cerebral Artery (MCA) that could have full clinical, neuroima-
ging and cellular evaluation within 24 h after the onset of symptoms
were included (Supplementary Fig. 1 presents the flow chart for study
participation, including exclusion criteria). All patients or legal re-
presentatives signed written informed consent for study participation.
The study design was approved by the local ethics committee (Ref. 130-
CE-2011).
At hospital presentation we collected demographic variables, vas-
cular risk factors and quantified stroke severity using the National
Institute of Health Stroke Scale (NIHSS) [9]. Functional outcome was
graded in person at three months according to the modified Rankin
scale (mRS) by vascular neurologist blinded to CBF and in vitro data.
2.2. Study design
At day zero (first 24 h after symptom onset) we collected patients'
blood for cellular isolation and performed clinical and hemodynamic
evaluation. At day 7 ± 2 days patients underwent MRI, repeated he-
modynamic evaluation and blood collection for cellular studies. At
3 months ± one week participants had repeated clinical and hemo-
dynamic evaluation. The primary objectives were to determine the as-
sociations between the number and functional properties of EPCs with
CBF, hemorrhagic transformation, recanalization and flow diversion
after ischemic stroke. We also aimed to understand the role of EPCs and
CBF within clinical and demographic features as secondary objectives.
2.3. Isolation of EPC sub-populations
We isolated EPCs from 18 mL of peripheral venous blood collected
in the first day and at day seven after stroke onset in accordance to
previously validated protocols [1,2]. Mononuclear cells (MNC) were
isolated from peripheral blood by density gradient centrifugation using
Lymphoprep™ density gradient medium.
Three different types of EPCs were analyzed: circulating angiogenic
cells (CACs), outgrowth Endothelial Progenitor Cells (oEPCs) and
colony forming unit-endothelial cells (CFU-ECs). For CACs, MNCs were
plated into 2 μg/cm2 fibronectin-coated plates (24-well plates;
1.9 × 106 cells/well) and cultured in Endothelial Growth Medium-2
Microvascular (EGM-2 MV) containing 5% fetal bovine serum (FBS)
during five days. Adherent cells were detached using trypsin, counted
and used for functional assays.
For oEPCs and CFU-ECs, 10 × 106 MNCs in Endothelial Growth
Medium-2 (EGM-2) with 10% FBS were seeded into one well of 2 μg/
cm2 fibronectin-coated 24-well plate. After 48 h, nonadherent cells
were collected and 3 × 106 cells were replated into three fibronectin-
coated 24-well plates. At day 5, colony-forming units were counted
manually in four random fields (20× magnification). The CFU-ECs
were detached using trypsin and used for functional studies [10]. The
adherent cells at 48 h continued cell culture for 14–21 days [11] to
obtain oEPCs. Medium for oEPCs and CFU-ECs was changed every 48 h.
All incubation periods were performed at 37 °C and 5%CO2.
2.4. Functional tests of EPCs
The wound healing capacity of oEPCs and CFU-ECs was evaluated
using the in vitro wound-healing (scratch) assay. In brief, cells were
plated in 2 μg/cm2 fibronectin-coated 96-well plates and cultured until
they form a monolayer. Then, the wounds were created by scratching
the cell layer with a 200 μL pipette tip. Migratory capacity was quan-
tified as the percentage of wound closure after 24 h (Fig. 1).
The angiogenic capacity of oEPCs and CFU-ECs were determined by
the sprout formation on Matrigel (using an IBIDI μ-slide angiogenesis
kit). The total tube length and number of branching points (i.e. points
featuring more than two connections) were manually measured in four
random fields (20× magnification) 24 h after plating (Fig. 1).
The migratory capacity of CACs was determined by transwell mi-
gration. In short, 2 × 104 CACs were placed in the upper chamber of a
modified Boyden chamber (2 μg/cm2 fibronectin-coated). The chamber
was placed in a 24-well culture dish containing EBM-2 and human re-
combinant VEGF (50 ng/mL) and incubated for 24 h. The lower side of
the filter was then washed with PBS and fixed with 4% paraformalde-
hyde. For quantification, cell nuclei were stained with 4′,6-diamidino-
2-phenylindole. Cells migrating into the lower chamber were counted
manually in 3 random microscopic fields (20× magnification).
Fig. 1. Representation of in vitro wound healing and angiogenesis assays (A and B respectively). Examples with enhanced (C and D) and poor properties (E and F) in each test are shown.
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2.5. Hemodynamic evaluation
The hemodynamic evolution was assessed through serial cervical
and transcranial neurosonological exams at admission (day zero), six
hours, seven days and three months after stroke (3 MHz sector-probe
and 11 MHz linear-probe respectively; General Electric Logiq7). All
exams were performed with patients lying in a supine position after at
least 10 min rest, collecting data on flow diversion, recanalization and
CBF. Flow velocities were assessed bilaterally using transcranial colour
coded Doppler (TCCD) with angle correction in anterior, middle and
posterior cerebral arteries (ACA, MCA and PCA respectively). Flow di-
version was defined as a high-velocity, low-resistance flow signal in the
ACA-A1 or PCA (P1–P2 segments) ipsilateral to the occluded MCA; the
ACA or PCA flow velocity had to be equal to or higher than the non-
affected MCA [12]. Recanalization was defined as grades four or five by
the Thrombolysis in Brain Ischemia scale in the TCCD performed six
hours after symptom onset. Cerebral blood flow (CBF) was quantified as
the sum of flow volumes in both internal carotid arteries (ICA) and
vertebral arteries (VA) (Fig. 2A). Intravascular flow volumes were de-
termined by the ultrasound equipment's software using the angle-cor-
rected mean flow velocity and the vessel's luminal diameter perpendi-
cular to its longitudinal axis at the same location as the flow
measurement [13]. ICAs were assessed at least 2 cm after bifurcation
and VAs in their V2 segment, at the C4-C5 intertransverse area. All
arteries were measured in a straight segment for three times and the
calculated mean taken for CBF analysis.
2.6. Neuroimaging
Hemorrhagic transformation was classified in the gradient echo
sequences of the MRI performed on day seven. Only type 2 par-
enchymal hemorrhages (PH2) were considered as hemorrhagic trans-
formation [14].
2.7. Statistical analysis
Normality of all study variables was assessed by the Shapiro-Wilk
test. The association of patients' demographics and vascular risk factors
with CBF at admission, seven days and three months was evaluated
using independent samples t-test, Pearson or Spearman correlation as
indicated by the variables' characteristics. We determined the in-
dependent association of EPCs cell number and functional properties
with CBF at different timepoints using multivariable linear regression.
To evaluate the association of EPC cell number and functional prop-
erties with hemorrhagic transformation, recanalization and flow di-
version we used binary logistic multivariate regressions. We then as-
sessed the association of CBF, hemorrhagic transformation,
recanalization and flow diversion with mRS at three months through
uni- and multivariable ordinal regression. All univariate analysis were
Fig. 2. Quantification of Cerebral Blood Flow (CBF). In (A) the identification of both
Internal Carotid Arteries (ICA) and Vertebral Arteries (VA) is shown in continuous colour
Doppler images. The parallelogram shown in yellow indicates the colour box steer in the
right-to-left/caudal-cephalic orientation of flow. The vessel diameter used for the quan-
tification of CBF is measured for each artery and indicated as the number “1”. (B) and (C)
represent the blood flow velocity analysis (in cm/seg) during two cardiac cycles of two
patients: patient represented in (B) has milder NIHSS at admission, flow diversion and
higher CBF than the patient in (C). The blue line in each flow analysis represents the mean
flow velocity (used for CBF quantification) and the yellow line indicates the maximum
flow velocity. (For interpretation of the references to colour in this figure legend, the
reader is referred to the web version of this article.)
Table 1
Univariate association of baseline variables with Cerebral Blood Flow (CBF) at day zero.
In the first rows the mean CBF of patients with and without dichotomous variables is
presented. In the bottom rows the correlation coefficients between CBF and continuous
variables are presented. All p-values presented are corrected for multiple comparisons.
CBF at day 0 p
With risk factor Without risk factor
Male gender 481.3 (119.6) 438.0 (167.9) 0.717
Hypertension 448.7 (129.3) 489.1 (178.4) 0.739
Diabetes mellitus 516.1 (118.0) 446.4 (148.8) 0.550
Atrial fibrillation 457.3 (171.0) 464.2 (113.0) 0.964
Dyslipidemia 443.2 (126.4) 507.0 (182.9) 0.616
Hyperuricemia 433.8 (115.6) 470.7 (154.5) 0.670
Heart failure 493.3 (208.7) 457.4 (139.9) 0.881
Ischemic heart disease 505.8 (161.0) 453.5 (142.9) 0.704
Previous stroke 385.0 (131.5) 464.2 (145.6) 0.717
Smoking 478.5 (158.7) 458.8 (145.2) 0.925
Peripheral artery disease 523.5 (151.5) 454.3 (144.4) 0.736
Obesity 418.2 (113.7) 487.3 (157.2) 0.546
Previous statin 414.9 (101.4) 482.0 (157.8) 0.565
Previous antiplatelet 445.7 (119.0) 464.5 (134.0) 0.908
Intravenous thrombolysis 499.8 (144.7) 404.0 (127.8) 0.213
Hemorrhagic transformation 451.6 (135.4) 461.8 (147.4) 0.884
Recanalization 509.9 (134.9) 426.5 (143.6) 0.325
Flow diversion 519.3 (136.6) 375.9 (112.5) 0.022⁎
Correlation coefficient
NIHSS at admission −0.414 0.055
Glucose at admission 0.057 0.928
Age −0.024 0.919
Weight −0.191 0.523
⁎ p < 0.05.
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corrected for multiple comparisons by false discovery rate, and the
corrected p-values are presented. All multivariable models included the
variables with p < 0.1 in univariate association with CBF at any
timepoint (NIHSS and flow diversion) as well as intravenous throm-
bolysis, due to its recognized clinical and hemodynamic effect.
Statistical significance was set for p < 0.05.
The sample size calculation was based on estimating large treatment
effects (d = 0.8) due to stringent inclusion criteria, a between-group
comparison with a 0.05 one-sided alpha significance level and 80%
power, that would require a total sample population of 42 patients. We
included 45 patients to account for potential dropouts and technical
failures in MRI.
2.8. Data availability
The datasets generated during and/or analyzed during the current
study are available from the corresponding author on reasonable re-
quest.
3. Results
We included a total of 45 patients in our study population, median
age 70 years, (interquartile range: 10) and 24 (53.3%) male. At three
months 5 (11.1%) were dead and 22 patients (48.9%) showed good
clinical outcome (mRS between 0 and 2). Univariate associations of
baseline characteristics with CBF at days zero are presented in Table 1
(in Supplementary Table 1 we present the univariate associations of
Table 2
Association of cellular variables at days zero and seven with CBF at day zero, day seven and 3 months. All results were obtained by multivariable regression adjusted for baseline NIHSS,
intravenous thrombolysis and flow diversion. SE: Standard Error
Variable CBF at day 0 CBF at day 7 CBF at 3 months
B (SE) p B (SE) p B (SE) p
Day 0 CAC number 0.189 (0.124) 0.134 0.273 (0.156) 0.09 0.189 (0.143) 0.197
oEPC number 0.101 (0.267) 0.707 0.481 (0.329) 0.154 0.161 (0.287) 0.579
CFU-EC number 0.079 (0.292) 0.787 −0.333 (0.382) 0.39 −0.2 (0.313) 0.528
CAC migration −4.076 (1.496) 0.01⁎ −0.011 (2.097) 0.996 0.953 (2.088) 0.651
oEPC migration 0.381 (1.084) 0.729 1.35 (1.431) 0.359 0.59 (1.182) 0.625
CFU-EC migration 1.954 (0.957) 0.052 0.37 (1.419) 0.797 −0.341 (1.229) 0.784
oEPC sprout number −0.852 (1.662) 0.612 3.125 (1.968) 0.127 3.518 (1.922) 0.081
CFU-EC sprout number −1.778 (1.755) 0.32 4.913 (1.836) 0.014⁎ 1.699 (2.022) 0.411
oEPC sprout length −0.04 (0.014) 0.789 0.016 (0.017) 0.34 0.028 (0.016) 0.096
CFU-EC sprout length −0.01 (0.017) 0.554 −0.024 (0.02) 0.235 0.013 (0.018) 0.476
Day 7 CAC number 0.061 (0.257) 0.816 0.144 (0.219) 0.516
oEPC number 0.886 (0.414) 0.041⁎ 0.423 (0.316) 0.191
CFU-EC number 0.396 (0.35) 0.267 0.636 (0.32) 0.057
CAC migration 1.244 (2.433) 0.612 1.506 (1.903) 0.435
oEPC migration 0.641 (1.492) 0.674 2.294 (2.148) 0.311
CFU-EC migration 1.6 (1.014) 0.133 1.68 (1.248) 0.2
oEPC sprout number 3.433 (1.486) 0.03⁎ 1.12 (1.471) 0.455
CFU-EC sprout number 2.404 (1.881) 0.214 −1.056 (1.806) 0.565
oEPC sprout length 0.021 (0.007) 0.009⁎ 0.009 (0.007) 0.259
CFU-EC sprout length 0.033 (0.02) 0.108 0.024 (0.018) 0.211
⁎ p < 0.05.
Table 3
Association of EPC cell number and functional properties with recanalization, flow diversion and hemorrhagic transformation. Results were obtained by multivariable regression adjusted
for baseline NIHSS, intravenous thrombolysis and flow diversion.
Variable Recanalization Flow diversion Hemorrhagic transformation
OR(95%CI) p OR(95%CI) p OR(95%CI) p
Day 0 CAC number 1.004 (0.998–1.01) 0.163 1.001 (0.997–1.006) 0.544 0.992 (0.979–1.005) 0.213
oEPC number 1.006 (0.996–1.016) 0.225 0.989 (0.976–1.002) 0.11 1.001 (0.984–1.018) 0.893
CFU-EC number 1.004 (0.993–1.016) 0.454 1.003 (0.992–1.013) 0.616 0.997 (0.978–1.016) 0.723
CAC migration 0.992 (0.934–1.052) 0.779 1.066 (0.994–1.143) 0.073 0.88 (0.746–1.038) 0.13
oEPC migration 0.986 (0.945–1.029) 0.531 1.04 (1.0–1.081) 0.053 1.036 (0.975–1.101) 0.249
CFU-EC migration 0.983 (0.945–1.023) 0.404 1.049 (1.003–1.096) 0.036⁎ 0.969 (0.908–1.033) 0.333
oEPC sprout number 0.965 (0.901–1.034) 0.312 1.101 (1.022–1.187) 0.012⁎ 1.021 (0.93–1.121) 0.663
CFU-EC sprout number 0.966 (0.904–1.033) 0.313 1.289 (0.991–1.672) 0.059 0.995 (0.906–1.092) 0.909
oEPC sprout length 1.0 (1.0–1.001) 0.549 1.0 (1.0–1.001) 0.46 1.001 (1.0–1.002) 0.11
CFU-EC sprout length 1.0 (0.999–1.001) 0.417 1.004 (1.0–1.008) 0.037⁎ 0.998 (0.994–1.002) 0.369
Day 7 CAC number 0.995 (0.982–1.007) 0.404
oEPC number 0.984 (0.956–1.013) 0.269
CFU-EC number 1.0 (0.983–1.017) 0.996
CAC migration 0.966 (0.864–1.081) 0.551
oEPC migration 1.002 (0.936–1.072) 0.955
CFU-EC migration 0.992 (0.94–1.048) 0.782
oEPC sprout number 0.95 (0.837–1.079) 0.432
CFU-EC sprout number 0.797 (0.511–1.245) 0.319
oEPC sprout length 1.0 (0.999–1.001) 0.662
CFU-EC sprout length 0.998 (0.994–1.003) 0.998
⁎ p < 0.05.
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baseline variables with CBF at day seven and three months). At day
zero, CBF was associated with the presence of flow diversion, with no
statistically significant associations at day seven nor day 90. Fig. 2 (B
and C) represents the flow velocities in two patients with distinct CBF
and clinical outcome.
The multivariable associations of CBF at different timepoints with
number and functional properties of EPCs are presented in Table 2. At
day zero, CBF was associated with the migratory properties of CACs.
CBF at day seven was associated with the angiogenic properties of day
zero CFU-ECs and day seven oEPCs. At three months no statistically
significant associations were identified between CBF and EPC proper-
ties. No cellular variable was associated with recanalization nor he-
morrhagic transformation on multivariable analyses (Table 3). Flow
diversion showed an independent association with oEPC sprout
number, CFU-EC migration and sprout length at day zero (Fig. 3).
We also evaluated the association of each hemodynamic variable
with functional outcome at three months (Table 4). Recanalization and
flow diversion were independently associated with a better clinical
outcome.
Fig. 3. Association of the functional properties of EPCs at day zero with recanalization (Recan.), flow diversion and hemorrhagic transformation (HT). Values are presented as mean and
95% confidence interval. *p < 0.05. Flow diversion is presented as “good” or “poor”.
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4. Discussion
The main finding of our study is the association of EPC properties
such as angiogenesis and migration with hemodynamic properties,
namely increased flow diversion at day zero and CBF at day seven. Our
results further show no statistical association between EPC properties
and recanalization or hemorrhagic transformation.
The associations between the angiogenic properties of oEPCs and
CFU-ECs with subacute CBF suggests the involvement of these cells in
the formation of new blood vessels. Yet, it is important to note that this
association was not visible in all functional tests, nor for all EPC
lineages. In fact, previous studies in mice have demonstrated a weak
but significant association between angiogenesis and CBF, which is
more pronounced after seven days [15] and prolongs at least up to
21 days [16]. This subacute association of angiogenesis with CBF is
reinforced by recent findings associating blood-brain barrier perme-
ability of stroke patients at seven days with good clinical outcome and
more proficient EPCs [2], and are in line with our current results, where
no association was found between EPCs and CBF at three months.
Moreover, the interpretation of our data within these previous reports,
support the notion that the hemodynamic impact of the EPCs can only
be partially explained by the effect of angiogenesis on CBF [16], as
could be expected considering the anatomically restricted area of
neoangiogenesis in comparison to the more widespread evaluation
implicated in CBF. An alternative mechanism relates to the possibility
that the presence of EPCs with enhanced functional properties might be
a marker of a more proficient vascular response to the ischemic insult
and not a local consequence of their action, although the concomitant
association with flow diversion and the dampening of effect at three
months suggests a more direct relation.
Flow diversion in the acute stage was associated with CBF at day
zero, functional properties of day zero EPCs and functional outcome at
three months. The link between angiogenesis and collateral circulation
has been suggested in previous animal model studies [17,18], but had
never been studied in humans. The biological mechanisms implied in
the development of collateral circulation in the context of an ischemic
insult seem to vary over time. In the acute and subacute stages two
processes appear to promote collaterals: shear fluid stress precipitated
by the pressure gradient caused by the acute thrombus and angiogen-
esis, as hypoxia triggers endothelial cells to sprout and form capillary
networks [19]. In this last critical step, EPCs take a pivotal role through
their paracrine (mainly through CAC subpopulation) and direct angio-
genic properties (mostly oEPCs and CFU-ECs). As stated earlier, the
association of flow diversion in the first hours after stroke with the
functional properties of EPCs may also suggest that both mechanisms
(EPCs and flow diversion) may coexist as markers of an efficient re-
sponse to stroke.
A potential offset of promoting a network of new vessels is he-
morrhagic transformation. In fact, previous studies on animal models
have yielded conflicting results considering the relation between an-
giogenesis and angiogenic factors (such as VEGF) with hemorrhagic
transformation [16,20]. Nonetheless, this seems to be a time-dependent
response: in the first hours after stroke VEGF promotes acute BBB dis-
ruption with hemorrhagic transformation, whereas in the subacute
stage the enhancement of effective neoangiogenesis improves CBF and
neurological recovery [16,20]. Our study supports the concept that in
stroke patients enhanced functional properties of EPCs promote flow
diversion with no effect on hemorrhagic transformation.
No effect was identified by EPCs on early arterial recanalization.
Although no previous study had assessed the association of EPCs with
recanalization in ischemic stroke, early works on EPCs suggested the
rationale for an effect on recanalization, albeit being more likely on
venous thrombi, due to the organization of fibrin meshwork and cel-
lular composition of the venous thrombi [21].
Our study has inherent limitations that should be taken under
consideration in its interpretation. Firstly it was a single centre study
with a relatively reduced sample size, however, the strict inclusion
criteria and features of the study population suggest external general-
izability of the findings. Moreover, cellular assessment at two time-
points may be limited within the intricate pathology of stroke.
Nonetheless, these timepoints have been suggested as pathologically
important in preclinical studies and are both potential treatment win-
dows in stroke patients. Moreover, performing comprehensive and se-
rial evaluations of hemodynamic and neurological status allowed a
rational and clinically meaningful interpretation of results.
5. Concusions
The functional properties of EPCs are associated with enhanced flow
diversion and subacute CBF, with no impact on recanalization nor he-
morrhagic transformation. These results promote the need and help the
design of interventional trials on the efficacy of EPCs in acute stroke,
reinforcing the integration of these cellular therapies within current
therapies.
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Table 4
Associations of hemodynamic variables with functional outcome at three months (multivariate ordinal regressions are adjusted for NIHSS, intravenous thrombolysis and flow diversion).
The p-values presented in univariate analysis are corrected for multiple comparisons. mRS: modified Rankin scale; CBF: Cerebral Blood Flow; OR: Odds Ratio; CI: Confidence Interval.
Variable mRS at 3 months
Univariate
OR (95%CI)
p mRS at 3 months
Multivariable
OR (95%CI)
p
CBF at day 0 −0.005 (−0.009 to −0.001) 0.020⁎ 0.001 (−0.004 to 0.006) 0.607
CBF at day 7 −0.004 (−0.008 to 0.000) 0.084 −0.003 (−0.008 to 0.001) 0.159
CBF at 3 months −0.004 (−0.009 to 0.001) 0.109 −0.005 (−0.011 to 0.001) 0.093
Recanalization −2.670 (−3.994 to −1.347) < 0.001⁎ −1.718 (−3.150 to −0.286) 0.019⁎
Hemorrhagic transformation 1.207 (−0.466 to 2.881) 0.157 1.546 (−0.336 to 3.428) 0.107
Flow diversion −3.751 (−5.319 to −2.184) < 0.001⁎ −3.416 (−5.005 to −1.827) < 0.001⁎
⁎ p < 0.05.
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Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jns.2017.12.028.
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